CBIO NASDAQ
Crescent Biopharma, Inc.
1W: +12.5%
1M: -0.3%
3M: -31.7%
YTD: +52.8%
1Y: +30.0%
3Y: -89.7%
5Y: -91.9%
$16.44
-0.49 (-2.89%)
Weekly Expected Move ±11.1%
$13
$14
$16
$18
$20
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$12.4M
Congress—
ETF Holdings—
Key Statistics
Market Cap$453.3M
52W Range8.72-27.41
Volume232,030
Avg Volume354,532
Beta1.19
Dividend—
Analyst Ratings
Company Info
CEOJoshua T. Brumm
Employees44
SectorHealthcare
IndustryBiotechnology
IPO Date2014-01-10
Websitecrescentbiopharma.com
300 Fifth Avenue
Waltham, MA 02451
US
Waltham, MA 02451
US
617-430-5595
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Fairmount Funds Mana | P-Purchase | 853,450 | $14.50 | 2026-07-16 |
| Lynch Ryan | S-Sale | 465 | $17.99 | 2026-06-22 |
| Pinkas Jan | S-Sale | 1,288 | $17.99 | 2026-06-22 |
| Scalzo Richard Willi | S-Sale | 1,112 | $17.99 | 2026-06-22 |
| Bispham Barbara Harl | S-Sale | 1,218 | $17.99 | 2026-06-22 |